The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

28 days Prescribing information NPH, human insulin isophane suspension (rDNA origin) Novolin N vial (Novo Nordisk) 30 days Prescribing information Regular human insulin injection (rDNA origin ...

Ozempic weight-loss drug maker Novo Nordisk on Wednesday expanded an existing agreement with a drug developer that uses artificial intelligence. Novo Nordisk said an agreement reached last year ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Novo Nordisk (NVO) ended the recent trading session at $84.62, demonstrating a -1.9% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%. At the same ...